CN113252909B - 一种基于量子点免疫荧光检测试剂盒制备方法 - Google Patents
一种基于量子点免疫荧光检测试剂盒制备方法 Download PDFInfo
- Publication number
- CN113252909B CN113252909B CN202110658191.0A CN202110658191A CN113252909B CN 113252909 B CN113252909 B CN 113252909B CN 202110658191 A CN202110658191 A CN 202110658191A CN 113252909 B CN113252909 B CN 113252909B
- Authority
- CN
- China
- Prior art keywords
- temperature
- glass fiber
- detection line
- fiber membrane
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 130
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000002096 quantum dot Substances 0.000 title claims description 28
- 238000010166 immunofluorescence Methods 0.000 title claims description 24
- 239000004005 microsphere Substances 0.000 claims abstract description 100
- 239000003365 glass fiber Substances 0.000 claims abstract description 53
- 239000012528 membrane Substances 0.000 claims abstract description 53
- 230000008878 coupling Effects 0.000 claims abstract description 26
- 238000010168 coupling process Methods 0.000 claims abstract description 26
- 238000005859 coupling reaction Methods 0.000 claims abstract description 26
- 238000003908 quality control method Methods 0.000 claims abstract description 18
- 108010051335 Lipocalin-2 Proteins 0.000 claims abstract description 16
- 230000004913 activation Effects 0.000 claims abstract description 10
- 238000005070 sampling Methods 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 80
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- 238000002156 mixing Methods 0.000 claims description 24
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 18
- 238000005507 spraying Methods 0.000 claims description 18
- 230000003213 activating effect Effects 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 14
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 12
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 claims description 12
- 239000003761 preservation solution Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 9
- 239000010931 gold Substances 0.000 claims description 9
- 229910052737 gold Inorganic materials 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- 238000007789 sealing Methods 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 239000005018 casein Substances 0.000 claims description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 7
- 235000021240 caseins Nutrition 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004327 boric acid Substances 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- -1 polyoxyethylene Polymers 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 229910021538 borax Inorganic materials 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 239000002274 desiccant Substances 0.000 claims description 3
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 239000004328 sodium tetraborate Substances 0.000 claims description 3
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 claims 12
- 239000012530 fluid Substances 0.000 claims 1
- 102000013519 Lipocalin-2 Human genes 0.000 abstract description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 description 17
- 208000033626 Renal failure acute Diseases 0.000 description 17
- 201000011040 acute kidney failure Diseases 0.000 description 17
- 206010061481 Renal injury Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 102000013382 Gelatinases Human genes 0.000 description 3
- 108010026132 Gelatinases Proteins 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000037806 kidney injury Diseases 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110658191.0A CN113252909B (zh) | 2021-06-15 | 2021-06-15 | 一种基于量子点免疫荧光检测试剂盒制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110658191.0A CN113252909B (zh) | 2021-06-15 | 2021-06-15 | 一种基于量子点免疫荧光检测试剂盒制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113252909A CN113252909A (zh) | 2021-08-13 |
CN113252909B true CN113252909B (zh) | 2021-10-08 |
Family
ID=77188101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110658191.0A Active CN113252909B (zh) | 2021-06-15 | 2021-06-15 | 一种基于量子点免疫荧光检测试剂盒制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113252909B (zh) |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012113773A1 (en) * | 2011-02-22 | 2012-08-30 | Roche Diagnostics Gmbh | Diagnosis of ischemia using sflt-1 and hgf after intervention as an early indicator of complication |
CN104483477B (zh) * | 2014-10-30 | 2017-07-28 | 南京肯辛顿诊断科技有限公司 | 偶联免疫磁珠的肌钙蛋白诊断试纸条的制备方法 |
CN204422546U (zh) * | 2014-12-29 | 2015-06-24 | 霍普金斯医药研究院(北京)有限责任公司 | 肾损伤五合一检测卡 |
CN205333654U (zh) * | 2016-01-21 | 2016-06-22 | 深圳市博卡生物技术有限公司 | 基于生物标志物的肾损伤早期检测试纸条 |
US20190353649A1 (en) * | 2016-12-01 | 2019-11-21 | University Of Florida Research Foundation, Inc. | Polymer conjugates, methods of making polymer conjugates, and methods of using polymer conjugates |
US20180275135A1 (en) * | 2017-03-22 | 2018-09-27 | Children's Hospital Medical Center | Biomarker panel to identify steroid resistance in childhood idiopathic nephrotic syndrome |
CN206804667U (zh) * | 2017-06-14 | 2017-12-26 | 江苏扬新生物医药有限公司 | 一种用于肾衰快速定量检测的多指标时间分辨荧光免疫层析试剂盒 |
CN107860910B (zh) * | 2017-11-06 | 2018-12-18 | 南京诺唯赞医疗科技有限公司 | 一种活化量子点的封闭方法 |
US20190317090A1 (en) * | 2018-04-12 | 2019-10-17 | Children's Hospital Medical Center | Compositions and methods for forecasting response to lupus nephritis (ln)therapy |
CN109342711B (zh) * | 2018-11-09 | 2019-08-09 | 吉林大学 | 多物种IL-1Ra与IL-1β及其比值同步测定的ELISA试剂盒 |
CN109813693A (zh) * | 2019-01-09 | 2019-05-28 | 北京丹大生物技术有限公司 | 一种检测万古霉素的时间分辨荧光免疫层析试纸条及其制备方法和应用 |
CN109799349B (zh) * | 2019-03-13 | 2022-05-24 | 石家庄洹众生物科技有限公司 | 一种联合定量检测卵巢储备功能多项指标的荧光免疫试纸条 |
CN110749731A (zh) * | 2019-10-18 | 2020-02-04 | 北京协和洛克生物技术有限责任公司 | 定量检测氧化低密度脂蛋白的时间分辨免疫层析试剂盒及应用 |
CN111961343B (zh) * | 2020-08-24 | 2022-07-12 | 中国药科大学 | 瞬时识别药物诱导hk-2细胞损伤的阵列传感器的制备方法及其应用 |
CN112285364A (zh) * | 2020-11-05 | 2021-01-29 | 南京申基医药科技有限公司 | 一种联合检测风湿三项的试剂盒及其制备方法 |
CN112198310B (zh) * | 2020-11-30 | 2021-03-02 | 南京申基医药科技有限公司 | 一种c反应蛋白和血清淀粉样蛋白a联合检测试纸条、试剂盒及试纸条的制备方法 |
-
2021
- 2021-06-15 CN CN202110658191.0A patent/CN113252909B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN113252909A (zh) | 2021-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11959912B2 (en) | Fluorescence immunochromatographic detection card and a preparation method therefor and use thereof | |
US9128099B2 (en) | Determination of sFlt-1:angiogenic factor complex | |
CN111413501A (zh) | 一种检测试纸条在制备检测thsd7a抗体的试剂盒中的应用 | |
CN111351945B (zh) | 维生素d结合蛋白作为标志物在精神疾病抑郁症诊断中的应用 | |
WO2004088311A1 (ja) | ノロウイルス又はサポウイルス検体用希釈液及びウイルス検出方法 | |
CN111610335A (zh) | 时间分辨荧光免疫层析试纸条、包含其的试剂盒及其应用 | |
CN202916286U (zh) | 一种定量检测降钙素原pct的胶乳增强免疫比浊试剂盒 | |
US20230049153A1 (en) | Quantitative kit for myxovirus resistance protein 1 | |
CN112269025A (zh) | 一种白介素-6化学发光测定试剂盒及其制备方法 | |
CN107271692B (zh) | 一种标记特异性高亲和力重组抗体的荧光微球及其应用 | |
CN113252909B (zh) | 一种基于量子点免疫荧光检测试剂盒制备方法 | |
AU2004223553B2 (en) | Latex reagent for adiponectin analysis and method of adiponectin analysis | |
CN112326975A (zh) | 心肌肌钙蛋白i、脑利钠肽和d-二聚体胸痛三联免疫荧光定量检测试剂盒 | |
JPH06104064B2 (ja) | 安定化酵素結合体組成物 | |
Hinberg et al. | Sensitivity of in vitro diagnostic dipstick tests to urinary protein | |
CN114112957B (zh) | 一种脂联素测定试剂盒及其应用 | |
CN112595845B (zh) | 透明质酸检测试剂盒及检测系统 | |
CN108548816A (zh) | 一种用于检测触珠蛋白含量的试剂盒 | |
US20240027471A1 (en) | Markers for predicting coronavirus disease 2019 (covid-19) immune checkpoint storm, application and kit thereof | |
CN114965986A (zh) | 用于检测血液中可溶性生长刺激表达基因2蛋白(st2)的试剂盒 | |
CN110456044B (zh) | 一种用于前列腺炎检测的试剂盒 | |
CN114295827A (zh) | 磁微粒吖啶酯化学发光检测试剂盒及其制备方法和应用 | |
JP3298812B2 (ja) | 尿中トリプシンインヒビターの測定方法 | |
EP1256802B1 (en) | Method for examination of feces occult blood | |
CN108414775A (zh) | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231019 Address after: No. 100, Binhe North Road, Karamay District, Karamay City, Xinjiang Uygur Autonomous Region 834000 (the fifth floor of the Experimental Testing Center) Patentee after: Xinjiang Shenji Biotechnology Co.,Ltd. Address before: 210000 building b6-2, No. 9, Weidi Road, Xianlin University City, Qixia District, Nanjing, Jiangsu Province Patentee before: Nanjing Shenji Pharmaceutical Technology Co.,Ltd. Patentee before: Xinjiang Shenji Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right |